Welcome to our dedicated page for Conformis news (Ticker: CFMS), a resource for investors and traders seeking the latest updates and insights on Conformis stock.
Conformis, Inc. (symbol: CFMS) is a leading medical technology company dedicated to enhancing orthopedic patient care. The company pioneers the development of patient-specific implants and instrumentation, offering unique advantages over traditional orthopedic solutions. Conformis' core mission is to optimize the fit and performance of implants by tailoring them to each patient's unique anatomy. This approach minimizes surgical trauma, preserves healthy tissue, and provides a more precise anatomic fit.
Conformis’ innovative product portfolio includes the Image-to-Implant® Platinum Services℠ Program and the Surgery-in-a-Box™ delivery system. These systems offer surgeons and patients fully personalized solutions and standardized options that combine the benefits of customization with the convenience of off-the-shelf systems. All implants come with single-use, patient-specific instruments, enhancing surgical efficiency and outcome.
Recently, Conformis has entered into a merger agreement with restor3d, Inc., a leader in 3D-printed orthopedic medical devices. This merger aims to create a dominant force in personalized 3D-printed medical devices by leveraging artificial intelligence-driven implant design, digital automation, and advanced osseointegrative biomaterials. The integration of Conformis' pioneering technology with restor3d’s expertise is anticipated to revolutionize the orthopedic industry further.
The merger has been unanimously approved by Conformis' Board of Directors and is expected to close by the end of Q3 2023, pending stockholder approval and customary closing conditions. Financial advisors for this transaction include UBS Investment Bank, with legal counsel from Hogan Lovells US LLP.
Conformis is headquartered in Billerica, Massachusetts, and continues to hold a strong position in the market, driven by its extensive portfolio of issued patents and pending patent applications covering personalized implants and patient-specific instrumentation for major joints.
Conformis, Inc. (NASDAQ:CFMS) announced the departure of Brent Alldredge, Chief Legal Officer, effective January 16, 2022. Alldredge will join Bruker Corporation as General Counsel. He will assist Conformis during the transition. CEO Mark Augusti praised Alldredge's contributions since 2019, highlighting his role in advancing the company's technologies.
Conformis specializes in personalized joint replacement implants using its proprietary iFit® Image-to-Implant® technology, positioning the company well for future growth.
Conformis, Inc. (NASDAQ:CFMS) announced the appointment of James Paiva as Vice President of U.S. Marketing, effective November 8, 2021. James brings 16 years of experience from Johnson & Johnson in marketing and business development, most recently as Senior Director of Marketing for DePuy Synthes. His expertise is expected to enhance Conformis' brand recognition and capitalize on growth opportunities in the ambulatory surgery center sector. Additionally, Paiva received a restricted stock unit award of 150,000 shares, vesting over four years, as part of his employment inducement.
Conformis, Inc. (NASDAQ:CFMS) reported third-quarter 2021 revenue of $14.3 million, a 12% decline year-over-year due to deferred elective surgeries related to the COVID-19 Delta variant. Product revenue also fell 12%, with hip system revenue down 16% to $0.7 million. Gross profit decreased to $6.0 million, impacting gross margin, which fell to 42%. The net loss widened to $13.0 million, compared to a loss of $6.2 million in Q3 2020. Despite challenges, Conformis anticipates fourth-quarter product revenue between $15.0 million and $17.0 million.
Conformis, Inc. (NASDAQ: CFMS) will announce its third-quarter financial results for the period ending September 30, 2021, on November 3, 2021. The results will be available after market close, around 4:00 p.m. ET. Following the release, CEO Mark Augusti and CFO Bob Howe will host a conference call at 4:30 p.m. ET to discuss the results and provide a business update. Interested parties can access the call via webcast or telephone. The company specializes in personalized joint replacement solutions, utilizing their iFit® technology platform.
Conformis, Inc. announced promising results from a retrospective study of its patient-specific iTotal® CR knee replacement implants. The study, involving 540 procedures, revealed an impressive 98.5% implant survivorship and 89% patient satisfaction over a mean follow-up period of 2.8 years. Functional outcomes were evaluated using the KOOS-JR questionnaire, yielding a high mean score of 82. These results reinforce Conformis' commitment to delivering quality products that enhance patient outcomes and support the company's long-term growth strategy.
Conformis (NASDAQ:CFMS) updated its third-quarter revenue expectations, forecasting between $13.7 million and $14.3 million, down from $15.5 million to $16.5 million. This adjustment is attributed to increased deferrals and rescheduling of knee and hip procedures due to the COVID-19 Delta variant surge. Despite these challenges, the company remains optimistic about its growth strategy and recent product additions. Management will present further insights at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21, 2021.
Conformis, a medical device company specializing in personalized orthopedic solutions, announced participation in two virtual investor conferences in September 2021. The first is the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, where on-demand presentations will be available. The second is the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 20-23, featuring a presentation by management on September 21 at 1:15 p.m. ET. Both events will offer opportunities for one-on-one meetings with management.
Conformis, Inc. (NASDAQ: CFMS) announced the first procedure using its new Identity Imprint knee replacement system on August 16, 2021, at Stratham Ambulatory Surgical Center. This system features both cruciate retaining and posterior stabilized implants, utilizing a proprietary algorithm to customize implant size based on individual CT scans. The system integrates with Conformis’ Surgery-in-a-Box delivery method, enhancing efficiency and cost savings for surgical centers. The global knee joint reconstruction market is expected to exceed $9 billion, with around 1 million replacements projected in the U.S. this year.
Conformis, Inc. (NASDAQ:CFMS) reported second-quarter 2021 revenue of $56.3 million, a 189% year-over-year increase. Product revenue rose to $15.2 million (+56%), while royalty and licensing revenue surged to $41.1 million due to a milestone payment from Stryker. Gross profit reached $47.5 million (84% gross margin), up from $11.0 million in Q2 2020. Net income was $38.0 million or $0.21 per share, compared to last year’s loss of $2.1 million. The company expects product revenue to rise sequentially in Q3, forecasting between $15.5 million and $16.5 million.
Conformis, Inc. (NASDAQ: CFMS) announced that CEO Mark Augusti and CFO Bob Howe will present at the Canaccord Genuity 40th Annual Growth Conference on August 11, 2021, at 4:00 p.m. ET. The presentation will be virtual, and interested parties can access a live webcast via Conformis' investor website. Additionally, management will offer one-on-one meetings throughout the conference. Conformis specializes in personalized orthopedic medical devices, utilizing its proprietary iFit® Image-to-Implant® technology to create custom joint replacements.
FAQ
What is the market cap of Conformis (CFMS)?
What does Conformis, Inc. specialize in?
What is the recent merger announcement involving Conformis?
What are the benefits of Conformis' patient-specific implants?
What is the Image-to-Implant® Platinum Services℠ Program?
What is the Surgery-in-a-Box™ delivery system?
Who are the financial and legal advisors for the Conformis merger?
What are the expected benefits of the merger with restor3d?
Where is Conformis headquartered?
How can investors get more information about Conformis?
What conditions need to be met for the merger to be completed?
